Social anxiety (SA) and depressive disorder usually coexist. Emotional Intelligence (EI) is a protective factor against emotional disorders. The aim of this study is to examine the moderating role of EI in the relationship between SA and depression among Spanish and Portuguese adolescents. Information on these variables was collected through a cross-sectional study with 1456 students between 12 and 19 years of age. The software PROCESS was used to perform the analysis of conditional processes (model 1). The moderation model was conducted, including the covariate country, and showed significant differences between countries in the relationship between SA and Depression. The summary model explained that 42% of the Depression. The statistical analysis was repeated separately for Portuguese and Spanish adolescents, with EI as the moderating variable. The effect of SA on depression was significant for individuals with low or moderate EI, while for adolescents with high EI there was no statistically significant effect. To prevent these outcomes, early interventions, including the enhancement of Trait EI, with adolescents with SA could reduce the risk of developing SA disorder, as well as subsequent depressive disorders in adolescence and early adulthood. This is especially important because research indicates that depression caused by SA is strongly associated with a worse course of depression.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10578-024-01795-yDOI Listing

Publication Analysis

Top Keywords

social anxiety
8
portuguese spanish
8
spanish adolescents
8
adolescents moderating
8
moderating role
8
emotional intelligence
8
relationship depression
8
depression
7
adolescents
5
anxiety depression
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

NA, Charlottesville, VA, USA.

Preclinical Alzheimer's prevention trials require a multi-year commitment from diverse, cognitively unimpaired individuals willing to receive biomarker results of confirmed Alzheimer's pathology and possible ApoE4 status. Participants learn new terms such as ARIA, edema and microhemorrhage and undergo numerous MRI scans for safety monitoring. They take quarterly composite Alzheimer's assessments that are anxiety-provoking and highlight weaknesses which may have been unrecognized in daily life.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Novo Nordisk A/S, Søborg, 2860 Søborg, Denmark.

Alzheimer's disease (AD) is a complex disease that is often accompanied by a range of comorbidities, such as cardiovascular disease, diabetes, and depression. These comorbidities can impact the progression of AD and can complicate treatment strategies. Targeting comorbidities in Alzheimer's disease and developing combination therapies are emerging areas of research.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.

Background: Participant dropout from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical trials for the full study duration is therefore as important as participant recruitment. This analysis aims to identify the baseline characteristics of participants who discontinued during the blinded phase of one of the first and largest preclinical AD trial completed to date, the Anti-Amyloid treatment in Asymptomatic AD (A4) Study.

View Article and Find Full Text PDF

Background: Apolipoprotein E4 (apoE4) has been identified as the major genetic risk factor for late onset Alzheimer's disease (AD). Our lab has demonstrated that chronic administration of Aβ12-28P, a synthetic peptide that blocks apoE4/Aβ binding, in middle-aged transgenic AD mice significantly ameliorates pathology progression, resulting in reduced Aβ plaques deposition and cerebral amyloid angiopathy (CAA) along with improved memory and cognition. However, whether blocking apoE4/Aβ interaction by Aβ12-28P also has an ameliorating effect on the neuronal and cognitive function of old AD mice where Aβ pathology has been extensively developed remains unknown.

View Article and Find Full Text PDF

Background: Aluminium chloride, an environmental toxicant induces neurotoxicity by increasing anxiety, causing cognitive deficit and memory impairment due to its effects on the hippocampus. Omega-3 oil has been shown to improve cognition in neurologic disorders.

Method: Forty adult female rats were divided into 4 groups (n = 10).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!